FORMULARY
A PEER-REVIEWED JOURNAL FOR MANAGED CARE AND HOSPITAL DECISION MAKERS

SUBJECT INDEX TO VOLUME 31

A

abciximab
angioplasty, for therapy after, 411 (May)
effect of, on overall Tx costs, 1018 (Nov)
long-term Tx with, 1113 (Nov)
targeting cost-effective use of, 186 (Mar)
academic detailing
tips on improving, 613 (Jul)
adapalene gel
Differin gel, 0.1%, update on, 731 (Sep)
adverse drug events
analyzing costs of, 399 (May)
enhancing program for reporting, 949 (Oct)
targeting, with cost-benefit analysis, 507 (Jun)
Agency for Health Care Policy and Research
controversies regarding, 138 (Feb)
AIDS
multidrug therapy is latest focus for, 265 (Apr)
opportunistic infections in patients with, Tx and prophylaxis of, 470 (Jun)
AIDS/HIV
state prescription program for, makes cutbacks, 882 (Oct)
albendazole tablets
Albenza, update on, 1033 (Nov)
albuterol sulfate, chlorofluorocarbon-free, metered-dose inhaler
Proventil HFA, update on, 1014 (Nov)
alendronate
focus on, 23 (Jan)
Fosamax, update on, 450 (Jun)
alteplase, recombinant
Activase, update on, 738 (Sep)
Alzheimer's disease
donepezil HCl for Tx of, 881 (Oct)
ENA-713 for Tx of, 881 (Oct)
amifostine
Ethyol, update on, 152 (Mar); 447 (Jun)
use of, in cisplatin-treated patients with head/neck cancer, 16 (Jan)
aminoglycosides
once-daily dosing of, 34 (Jan)
amiodarone
post MI, reduces mortality from arrhythmia, 412 (May)
amlodipine besylate
Norvasc, update on, 872 (Oct)
amoxicillin/clavulanate potassium
Augmentin, update on, 351 (May); 742 (Sep)
amphotericin B lipid complex
Abelcet, update on, 84 (Feb)
focus on, 169 (Mar)
amyotrophic lateral sclerosis
recombinant human insulin-like growth factor I improves symptoms of, 15 (Jan)
anastrozole
Arimidex Tablets, update on, 151 (Mar)
focus on, 363 (May)
anesthetic agent
Naropin, update on, 1141 (Dec)
angina, unstable
beta blockers for Tx of, 1114 (Nov)
angioplasty
thrombolysis, vs, for Tx after MI, 411 (May)
angiotensin-converting enzyme inhibitors
benefit of early Tx with, after MI, 67 (Jan)
coronary artery disease, seem to slow or reverse, 415 (May)
use of, in diabetic patients after MI, 413 (May)
angiotensin II type 1 receptor blockers
cardiovascular disease, for Tx of, 1058 (Nov)
antibiotics
controlling costs of, 712 (Aug)
controlling use of, resistance to, 1020 (Nov)
FDA offers accelerated approval for, when targeted at resistant microorganisms, 1027 (Nov)
nonrestrictive strategy for empiric use of (abstr), 530 (Jun)
pipeline swells, 1155 (Dec)
promoting appropriate prescribing of, based on renal function, 834 (Sep)
random cycling of, 652 (Aug)
anticoagulant therapy
arriving at optimal, in MI survivors (abstr), 984 (Oct)
antidepressants
costs associated with titration of, 164 (Mar)
selection of, in an HMO, 374 (May)
antiemetic agents
evaluating, 670 (Aug)
antihypertensive agents
reassessment of, since 1993 JNC recommendations, 116 (Feb)
antiplatelet therapy
coronary stenting, after, 67 (Jan)
antiretroviral therapy
update on, for Tx of HIV infection, 780 (Sep)
arcitumomab
CEA-Scan, update on, 1134 (Dec)
arthritis, rheumatoid
cyclosporine therapy lessens joint damage in (abstr), 983 (Oct)
methotrexate/sulfasalazine/hydroxychloroquine sulfate for Tx of (abstr), 854 (Sep)
aspergillosis
amphotericin B lipid complex for Tx of, 169 (Mar)
Association for Pharmacoeconomic and Outcomes Research
promoting research, and, 197 (Mar)
astemizole
Hismanal, update on, 450 (Jun)
asthma
Accolate, update on 1134 (Dec)
drawback of delaying corticosteroid therapy for (abstr), 1120 (Nov)
fluticasone propionate for management of, 1165 (Dec)
inhaled beta agonists for Tx of, 711 (Aug)
zafirlukast for prophylaxis and chronic Tx of, 1029 (Nov)
atherosclerosis, cardiovascular
role of HMG-CoA reductase inhibitors in preventing, 582 (Jul)
atrial fibrillation and flutter
adjusted-dose warfarin best for high-risk patients with (abstr), 1245 (Dec)
IV ibutilide for Tx of, 570 (Jul)
azithromycin
uncomplicated cervical chlamydial infections, for Tx of (abstr), 416 (May)
Zithromax, update on, 252 (Apr); 870 (Oct)

B

beclomethasone dipropionate
Vancenase AQ 84 µg Double Strength, update on, 742 (Sep)
benign prostatic hypertrophy
finasteride most effective in, in patients with largest prostates, 1162 (Dec)
terazosin more potent in all patient types, downplays importance of prostate size, 1162 (Dec)
beta agonists, inhaled
asthma, for Tx of, 711 (Aug)
beta blockers
heart failure, LV dysfunction, and unstable angina, appear useful for Tx of, 1114
low-dose, for Tx of patients with cardiomyopathy (abstr), 988 (Oct)
biologic agents
high-cost, developing reimbursement program for, 293 (Apr)
growing number of, in development, 746 (Sep)
bismuth subsalicylate, metronidazole, tetracycline
Helidac,update on, 1138 (Dec)
bleomycin sulfate, USP
Blenoxane, update on, 444 (Jun)
brimonidine tartrate ophthalmic solution 0.2%
Alphagan, update on, 1007 (Nov)
buffered intrathecal electrolyte/dextrose injection
Elliotts B Solution, update on, 1137 (Dec)

C

calcipotriene
Dovonex, update on, 872 (Oct)
calcitonin-salmon
Miacalcin Nasal Spray, update on, 13 (Jan); 160 (Mar)
calcium channel blockers
debate regarding use of, in patients with hypertension, 68 (Jan)
safety of, in patients with CAD (abstr), 988 (Oct)
cancer
breast:
anastrozole for Tx of, 363 (May)
docetaxel for Tx of locally advanced or metastatic, 891 (Oct)
head/neck:
amifostine, use of, in cisplatin-treated patients with, 16 (Jan)
nonsmall-cell lung:
paclitaxel/cisplatin for Tx of, 751 (Sep)
vinorelbine/cisplatin for Tx of, 705 (Aug)
ovarian:
cisplatin/paclitaxel for Tx of, 358 (May)
prostate:
advanced, nilutamide for Tx of, 105 (Feb)
hormone refractory, mitoxantrone for Tx of, 654 (Aug)
cancer patients, granulocytopenic
meropenem for Tx of fever in (abstr) 984 (Oct)
captopril
fails to improve aerobic/anaerobic capacity after MI (abstr), 323 (Apr)
nephropathy, slows development of, in normotensive patients with diabetes (abstr), 531 (Jun)
carbamazepine, extended-release
Tegretol, update on, 448 (Jun)
cardiovascular disease
angiotensin II type 1 receptor blockers for Tx of, 1058 (Nov)
care pathways
building, 887 (Oct)
critical, creating successful, 709 (Aug)
effects of, in patients with chronic heart failure, 527 (Jun)
carvedilol
mortality, reduces, in patients with chronic heart failure, 65 (Jan)
plus standard therapy for the Tx of congestive heart failure, 415 (May)
cefepime HCl
febrile neutropenia, for Tx of, 1112 (Nov)
Maxipime, update on, 251 (Apr)
cefixime

FORMULARY
A PEER-REVIEWED JOURNAL FOR MANAGED CARE AND HOSPITAL DECISION MAKERS

SUBJECT INDEX TO VOLUME 31

A

abciximab
angioplasty, for therapy after, 411 (May)
effect of, on overall Tx costs, 1018 (Nov)
long-term Tx with, 1113 (Nov)
targeting cost-effective use of, 186 (Mar)
academic detailing
tips on improving, 613 (Jul)
adapalene gel
Differin gel, 0.1%, update on, 731 (Sep)
adverse drug events
analyzing costs of, 399 (May)
enhancing program for reporting, 949 (Oct)
targeting, with cost-benefit analysis, 507 (Jun)
Agency for Health Care Policy and Research
controversies regarding, 138 (Feb)
AIDS
multidrug therapy is latest focus for, 265 (Apr)
opportunistic infections in patients with, Tx and prophylaxis of, 470 (Jun)
AIDS/HIV
state prescription program for, makes cutbacks, 882 (Oct)
albendazole tablets
Albenza, update on, 1033 (Nov)
albuterol sulfate, chlorofluorocarbon-free, metered-dose inhaler
Proventil HFA, update on, 1014 (Nov)
alendronate
focus on, 23 (Jan)
Fosamax, update on, 450 (Jun)
alteplase, recombinant
Activase, update on, 738 (Sep)
Alzheimer's disease
donepezil HCl for Tx of, 881 (Oct)
ENA-713 for Tx of, 881 (Oct)
amifostine
Ethyol, update on, 152 (Mar); 447 (Jun)
use of, in cisplatin-treated patients with head/neck cancer, 16 (Jan)
aminoglycosides
once-daily dosing of, 34 (Jan)
amiodarone
post MI, reduces mortality from arrhythmia, 412 (May)
amlodipine besylate
Norvasc, update on, 872 (Oct)
amoxicillin/clavulanate potassium
Augmentin, update on, 351 (May); 742 (Sep)
amphotericin B lipid complex
Abelcet, update on, 84 (Feb)
focus on, 169 (Mar)
amyotrophic lateral sclerosis
recombinant human insulin-like growth factor I improves symptoms of, 15 (Jan)
anastrozole
Arimidex Tablets, update on, 151 (Mar)
focus on, 363 (May)
anesthetic agent
Naropin, update on, 1141 (Dec)
angina, unstable
beta blockers for Tx of, 1114 (Nov)
angioplasty
thrombolysis, vs, for Tx after MI, 411 (May)
angiotensin-converting enzyme inhibitors
benefit of early Tx with, after MI, 67 (Jan)
coronary artery disease, seem to slow or reverse, 415 (May)
use of, in diabetic patients after MI, 413 (May)
angiotensin II type 1 receptor blockers
cardiovascular disease, for Tx of, 1058 (Nov)
antibiotics
controlling costs of, 712 (Aug)
controlling use of, resistance to, 1020 (Nov)
FDA offers accelerated approval for, when targeted at resistant microorganisms, 1027 (Nov)
nonrestrictive strategy for empiric use of (abstr), 530 (Jun)
pipeline swells, 1155 (Dec)
promoting appropriate prescribing of, based on renal function, 834 (Sep)
random cycling of, 652 (Aug)
anticoagulant therapy
arriving at optimal, in MI survivors (abstr), 984 (Oct)
antidepressants
costs associated with titration of, 164 (Mar)
selection of, in an HMO, 374 (May)
antiemetic agents
evaluating, 670 (Aug)
antihypertensive agents
reassessment of, since 1993 JNC recommendations, 116 (Feb)
antiplatelet therapy
coronary stenting, after, 67 (Jan)
antiretroviral therapy
update on, for Tx of HIV infection, 780 (Sep)
arcitumomab
CEA-Scan, update on, 1134 (Dec)
arthritis, rheumatoid
cyclosporine therapy lessens joint damage in (abstr), 983 (Oct)
methotrexate/sulfasalazine/hydroxychloroquine sulfate for Tx of (abstr), 854 (Sep)
aspergillosis
amphotericin B lipid complex for Tx of, 169 (Mar)
Association for Pharmacoeconomic and Outcomes Research
promoting research, and, 197 (Mar)
astemizole
Hismanal, update on, 450 (Jun)
asthma
Accolate, update on 1134 (Dec)
drawback of delaying corticosteroid therapy for (abstr), 1120 (Nov)
fluticasone propionate for management of, 1165 (Dec)
inhaled beta agonists for Tx of, 711 (Aug)
zafirlukast for prophylaxis and chronic Tx of, 1029 (Nov)
atherosclerosis, cardiovascular
role of HMG-CoA reductase inhibitors in preventing, 582 (Jul)
atrial fibrillation and flutter
adjusted-dose warfarin best for high-risk patients with (abstr), 1245 (Dec)
IV ibutilide for Tx of, 570 (Jul)
azithromycin
uncomplicated cervical chlamydial infections, for Tx of (abstr), 416 (May)
Zithromax, update on, 252 (Apr); 870 (Oct)

B

beclomethasone dipropionate
Vancenase AQ 84 µg Double Strength, update on, 742 (Sep)
benign prostatic hypertrophy
finasteride most effective in, in patients with largest prostates, 1162 (Dec)
terazosin more potent in all patient types, downplays importance of prostate size, 1162 (Dec)
beta agonists, inhaled
asthma, for Tx of, 711 (Aug)
beta blockers
heart failure, LV dysfunction, and unstable angina, appear useful for Tx of, 1114
low-dose, for Tx of patients with cardiomyopathy (abstr), 988 (Oct)
biologic agents
high-cost, developing reimbursement program for, 293 (Apr)
growing number of, in development, 746 (Sep)
bismuth subsalicylate, metronidazole, tetracycline
Helidac,update on, 1138 (Dec)
bleomycin sulfate, USP
Blenoxane, update on, 444 (Jun)
brimonidine tartrate ophthalmic solution 0.2%
Alphagan, update on, 1007 (Nov)
buffered intrathecal electrolyte/dextrose injection
Elliotts B Solution, update on, 1137 (Dec)

C

calcipotriene
Dovonex, update on, 872 (Oct)
calcitonin-salmon
Miacalcin Nasal Spray, update on, 13 (Jan); 160 (Mar)
calcium channel blockers
debate regarding use of, in patients with hypertension, 68 (Jan)
safety of, in patients with CAD (abstr), 988 (Oct)
cancer
breast:
anastrozole for Tx of, 363 (May)
docetaxel for Tx of locally advanced or metastatic, 891 (Oct)
head/neck:
amifostine, use of, in cisplatin-treated patients with, 16 (Jan)
nonsmall-cell lung:
paclitaxel/cisplatin for Tx of, 751 (Sep)
vinorelbine/cisplatin for Tx of, 705 (Aug)
ovarian:
cisplatin/paclitaxel for Tx of, 358 (May)
prostate:
advanced, nilutamide for Tx of, 105 (Feb)
hormone refractory, mitoxantrone for Tx of, 654 (Aug)
cancer patients, granulocytopenic
meropenem for Tx of fever in (abstr) 984 (Oct)
captopril
fails to improve aerobic/anaerobic capacity after MI (abstr), 323 (Apr)
nephropathy, slows development of, in normotensive patients with diabetes (abstr), 531 (Jun)
carbamazepine, extended-release
Tegretol, update on, 448 (Jun)
cardiovascular disease
angiotensin II type 1 receptor blockers for Tx of, 1058 (Nov)
care pathways
building, 887 (Oct)
critical, creating successful, 709 (Aug)
effects of, in patients with chronic heart failure, 527 (Jun)
carvedilol
mortality, reduces, in patients with chronic heart failure, 65 (Jan)
plus standard therapy for the Tx of congestive heart failure, 415 (May)
cefepime HCl
febrile neutropenia, for Tx of, 1112 (Nov)
Maxipime, update on, 251 (Apr)
cefixime

rifampin, vs, for prophylaxis against group A streptococci (abstr), 322 (Apr)
cefpodoxime proxetil
Vantin, update on, 877 (Oct)
cefprozil
Cefzil, update on, 1145 (Dec)
ceftibutin
Cedax, update on, 151 (Mar)
ceftizoxime
ceftriaxone, as therapeutic substitution for, 221 (Mar)
12-hour dosing regimen for, 304 (Apr)
ceftriaxone
ceftizoxime for therapeutic substitution of, 221 (Mar)
cefuroxime
Ceftin, update on, 557 (Jul)
cetirizine HCl
Zyrtec, update on, 1147 (Dec)
chlamydial infections, uncomplicated cervical
azithromycin for Tx of (abstr), 416 (May)
chlorzoxazone
Paraflex, Parafon Forte DSC, update on, 89 (Feb)
cholesterol-lowering drugs
benefits of, in normotensive post-MI patients, 413 (May)
chronic obstructive pulmonary disease
ipratropium better than beta agonists for long-term Tx of (abstr), 982 (Oct)
cidofovir injection
Vistide, update on, 738 (Sep)
ciprofloxacin
Cipro, update on, 1145 (Dec)
controlling resistance to, 70 (Jan)
gastroenteritis, for Tx of (abstr), 853 (Sep)
using DUE to improve prescribing of, in outpatients, 694 (Aug)
cisatracurium besylate
Nimbex, update on, 158 (Mar)
cisplatin/paclitaxel
ovarian cancer, for Tx of, 358 (May)
citocoline
ischemic stroke, seems to limit immediate damage from, 561 (Jul)
clarithromycin
Biaxin, update on, 88 (Feb); 160 (Mar); 870 (Oct)
H pylori resistance to, 1107 (Nov)
clinical pathway development program
how to start, 315 (Apr)
clinical pharmacy services
how to document cost-effectiveness of, 933 (Oct)
using cost-utility analysis to select, 684 (Aug)
clobetasol propionate
Temovate E, update on, 1014 (Nov)
coagulation factor IX, solvent-detergent treated/virus-filtered
Alpha-Nine SD, update on, 1014 (Nov)
colitis
polymer-coated oral mesalamine for Tx of (abstr), 532 (Jun)
colorectal carcinoma
CEA-Scan, update on, 1134 (Dec)
congestive heart failure
carvedilol for Tx of, 415 (May)
conjugated estrogens/medroxyprogesterone acetate
Prempro, Premphase, update on, 89 (Feb)
contrast agent
Feridex IV, update on, 1138 (Dec)
coronary artery disease
ACE inhibitors seem to slow or reverse development of, 415 (May)
secondary prevention of, pravastatin is cost-effective for (abstr), 1242 (Dec)
simvastatin, safety of, in patients with (abstr), 988 (Oct)
unstable, low molecular weight heparin reduces MI risk in patients with, 66 (Jan)
coronary stenting
antiplatelet therapy after, 67 (Jan)
enoxaparin/ticlopidine reduces ischemic events after, 414 (May)
corticosteroids
drawback of delaying therapy with, in asthma (abstr), 1120 (Nov)
expanded indications for, in Tx of asthma, 647 (Aug)
inhaled, as first-line therapy for asthma (abstr), 324 (Apr)
cromolyn sodium
Gastrocrom, update on, 557 (Jul)
cyclosporine
rheumatoid arthritis, lessens joint damage in (abstr), 983 (Oct)
cytomegalovirus immune globulin intravenous human
CytoGam, update on, 870 (Oct)

D

dalteparin sodium
Fragmin, update on, 351 (May); 872 (Oct)
daunorubicin citrate liposome injection
DaunoXome, update on, 551 (Jul)
deep vein thrombosis
prophylaxis against postoperative, 167 (Mar)
using published, institutional data, to evaluate cost effectiveness of prophylaxis of, 1203 (Dec)
delavirdine mesylate
update on, 160 (Mar)
depression
mirtazapine for Tx of, 455 (Jun)
dexfenfluramine HCl
focus on, 659 (Aug)
Redux, update on, 552 (Jul); 877 (Oct)
diabetes
angiotensin-converting enzyme for Tx of patients with, after MI, 413 (May)
captropil slows development of nephropathy in normotensive patients with (abstr), 531 (Jun)
sulfonylurea/insulin for controlling (abstr), 416 (May)
diclofenac sodium, extended-release
Voltaren-XR, update on, 450 (Jun)
didanosine
Videx, update on, 1013 (Nov)
digoxin
heart failure, for Tx of, 414 (May)
diltiazem HCl
Tiazac, update on, 160 (Mar); 351 (May)
diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed
Tripedia, update on, 1013 (Nov)
disease management program
asthma, stresses early intervention, 524 (Jun)
follow-up patient education can improve outcomes in, 1233 (Dec)
formularies must change to meet goals of, 1228 (Dec)
GI, using DUR criteria to develop, 755 (Sep)
keys to success of, 519 (Jun); 1234 (Dec)
pharmacists can make important contribution in, 1232 (Dec)
physician's view, pros and cons of, 1228 (Dec)
spending for, expected to soar, 1148 (Dec)
targeting diseases for, 135 (Feb)
divalproex sodium
Depakote, update on, 447 (Jun); 741 (Sep)
docetaxel
focus on, 891 (Oct)
Taxotere, update on, 552 (Jul)
donepezil HCl
Alzheimer's disease, for Tx of, 881 (Oct)
doxorubicin HCl liposome injection
Doxil, update on, 251 (Apr); 872 (Oct)
drug approvals
1995, 99 (Feb)
FDA promises to speed up, 236 (Mar)
drug development
factors that add time, cost to, 651 (Aug)
drug discounts
court ruling on discriminatory pricing may alter, 720 (Aug)
drug distribution
automated system for, 562 (Jul)
drug issues
rethinking approach to, 957 (Oct)
drug patents
debate regarding extension of, 534 (Jun)
drug resistance
FDA offers accelerated approval for antibiotics that target organisms with, 1027 (Nov)
keys to preventing, 751 (Sep)
vancomycin, not controlled by restrictions, 1105 (Nov)
drug utilization review
Medicaid, cost-effectiveness of, 95 (Feb)
duodenal ulcer
Helidac, update on, 1138 (Dec)

E

elderly patients
acute-care hospital costs in (abstr), 853 (Sep)
oral fluconazole for Tx of fungal UTI in (abstr), 718 (Aug)
electronic medical records
future replacement for formularies, as, 217 (Mar)
ENA-713
Alzheimer's disease, for Tx of, 881 (Oct)
enoxaparin/ticlopidine
coronary stenting, for Tx of patients after, 414 (May)
esophageal cancer
Photofrin for Injection, update on, 341 (May); 1145 (Dec)
estradiol vaginal ring
Estring, update on, 450 (Jun)
etodolac
Lodine, update on, 742 (Sep)
etoposide phosphate
Etopophos for Injection, update on, 742 (Aug)

F

famciclovir
Famvir, update on, 154 (Mar); 447 (Jun)
genital herpes, for early Tx of recurrent, 1120 (Nov)
genital herpes, for preventing reccurrence of, 1107 (Nov)
FDA
drug information regulations, proposes changes in, 624 (Jul)
reform legislation affecting, 330 (Apr)
reform of, stalled, 1122 (Nov)
felodipine, extended-release
switching to, from nifedipine GI therapeutic system (abstr), 717 (Aug)
fentanyl transmucosal system
Fentanyl Oralet, update on, 872 (Oct)
ferumoxides injectable solution
Feridex IV, update on, 1138 (Dec)

fexofenadine HCl
Allegra, update on, 866 (Oct)
filgrastim
Neupogen, update on, 448 (Jun)
finasteride
most effective in BPH patients with the largest prostates, 1162 (Dec)
5-HT_3 antiemetics
developing guidelines for cost-effective use of, 49 (Jan)
evaluation of, in emetogenic chemotherapy regimens, 1071 (Nov)
fluocinolone acetonide
Derma-Smoothe/FS Topical Oil, update on, 154 (Mar)
fluconazole
Diflucan, update on, 351 (May)
oral, as alternative Tx of fungal UTI in the elderly (abstr), 718 (Aug)
flunisolide 0.025% nasal solution
Nasarel, update on, 351 (May)
fluoxetine
DUE of, in psychiatric population, 842 (Sep)
enhances recovery in patients after hemiplegic stroke (abstr), 987 (Oct)
flutamide
Eulexin, update on, 741 (Sep)
fluticasone propionate inhalation aerosol
Flovent, update on, 448 (Jun)
focus on, 1165 (Dec)
fluvastatin
Lescol, update on, 351 (May)
formularies
Canadian health care system, in the, 960 (Oct)
changing from open to closed, 208 (Mar); 320 (Apr)
controlling drugs costs in, effective way of, 745 (Sep)
FDA's focus on, 74 (Jan)
HMOs using more, 352 (May)
need to adapt and evolve, 959 (Oct); 1228 (Dec)
open, improve oncology outcomes in managed care setting, 878 (Oct)
study on restrictive, flawed, 439 (Jun)
TennCare restrictions on, adversely affect patient care, costs, 443 (Jun)
VA to develop national one, drug treatment guidelines in redesign of drug benefit program, 1156 (Dec)
formulary decisions
method for collecting, evaluating outcomes of, 906 (Oct)
using value analysis to make, 1083 (Nov)
formulary maintenance programs
preferential agents and cost savings in, 1096 (Nov)
formulary management
one medical center's approach to, 917 (Oct)
formulary review
streamlining process for, 214 (Mar); 404 (May)
foscarnet sodium
Foscavir, update on, 741 (Sep)
fosphenytoin sodium injection
Cerebyx, update on, 869 (Oct)

G

gadodiamide injection
Omniscan, update on, 557 (Jul)
ganciclovir
Cytovene, update on, 88 (Feb)
ganciclovir intraocular implant system
Vitrasert, update on, 647 (Aug)
gastroenteritis
ciprofloxacin for Tx of (abstr), 853 (Sep)
gemcitabine HCl
Gemzar, update on, 639 (Aug)
gentamicin
once-daily dosing of, 34 (Jan)
glimepiride
Amaryl, update on, 11 (Jan)
glioblastoma multiforme
Gliadel Wafer, update on, 1147 (Dec)
goserelin acetate implant
Zoladex, update on, 158 (Mar); 252 (Apr)
granisetron
ondansetron, vs, cost-effectiveness of, 49 (Jan)

H

health care plans
providing consumers information about, 968 (Oct)
health insurance
legislation affecting, 856 (Sep)
health maintenance organizations
antidepressant selection and, 374 (May)
drug cost-saving strategies and, 257 (Apr)
formularies seen effective by, in survey, 745 (Sep)
health systems alliance
benefits of membership in, 968 (Oct)
heart failure
beta blockers for Tx of patients with, 1114 (Nov)
care pathways, effect of, in Tx of chronic, 527 (Jun)
carvedilol reduces mortality in patients with, 65 (Jan)
digoxin for Tx of, 414 (May)
Helicobacter pylori
clarithromycin, resistance to, 1107 (Nov)
eradication of, stressed in Tx of peptic ulcer (abstr), 530 (Jun)
Helidac, update on, 1138 (Dec)
heparin, low molecular weight
compared with standard heparin, 569 (Jul)
edged out by hirudin for acute coronary syndrome, 1151 (Dec)
reduces MI risk in patients with unstable coronary artery disease, 66 (Jan)
hepatitis A vaccine, inactivated
Havrix, update on, 647 (Aug)
Vaqta, update on, 554 (Jul)
hepatitis B vaccine plus haemophilus b vaccine
Comvax, update on, 1146 (Dec)
hepatitis C
interferon alfa, responds to higher dosages/longer course of, than approved by FDA, 1119 (Nov)
herpes, genital
oral famciclovir for preventing recurrence of, 1107 (Nov)
herpes, labialis
Denavir, update on, 1137 (Dec)
hirudin
edges out heparin for acute coronary syndrome, but cost-benefit ratio is uncertain, 1151 (Dec)
HIV infection
advanced, saquinavir for Tx of, 265 (Apr)
antiretroviral therapy for, 780 (Sep)
integrated approach to Tx of, 561 (Jul)
multidrug therapy latest focus for Tx of, 258 (Apr)
HMG-CoA reductase inhibitors
cardiovascular atherosclerosis, for preventing, 582 (Jul)
hydrocodone/acetaminophen
Anexsia, update on, 1014 (Nov)
hydrocodone bitartrate/acetaminophen
Lortab 10/500 CIII, update on, 872 (Oct)
hypertension
acute, appraisal of agents for Tx of, 1178 (Dec)
choice of initial Tx for (abstr), 853 (Sep)
use of calcium channel blockers in patients with, debate regarding, 68 (Jan)
hypotension
dialysis-induced, Tx of, 126 (Feb)

I

ibutilide fumarate injection
Corvert, update on, 248 (Apr)
focus on, 570 (Jul)
IDEC-C2B8
non-Hodgkin's lymphoma, for Tx of, 705 (Aug)
indinavir sulfate
Crixivan, update on, 547 (Jul)
infections
meropenem for Tx of, 759 (Sep)
insulin growth factor-1
Myotrophin, update on, 872 (Oct)
insulin lispro
Humalog, update on 639, (Aug)
integrated care
future of, 261 (Apr)
interferon alfa
hepatitis C responds to larger doses/longer course of, than approved by FDA, 1119 (Nov)
interferon alfa-2a, recombinant
Roferon-A, update on, 12 (Jan)
interferon alfa-2b, recombinant for injection
Intron A, update on, 88 (Feb)
interferon beta-1a
Avonex, update on, 636 (Aug)
interleukin-2/indinavir
CD4 counts, appears to increase, 1111 (Nov)
interstitial cystitis
Elmiron, update on, 1137 (Dec)
iodixanol
Visipaque Injection, update on, 554 (Jul)
ioxilan injection
Oxilan, update on, 552 (Jul)
ipratropium bromide
better than beta agonists for long-term Tx of COPD (abstr), 982 (Oct)
irinotecan HCl
Camptosar, update on, 869 (Oct)

L

lamivudine
Epivir Tablets and Oral Solution, update on, 12 (Jan)
lansoprazole
Prevacid, update on, 13 (Jan); 642 (Aug)
latanoprost solution
Xalatan, update on, 738 (Sep)
left ventricular dysfunction
beta blockers for treatment of, 1114 (Nov)
Legionnaire's disease
review of antibiotic approaches to therapy for, 808 (Sep)
leukemia, meningeal, or lymphocytic lymphoma
Elliotts B Solution, update on, 1137 (Dec)
leuprolide acetate suspension
Lupron, update on, 160 (Mar)
levocabastine HCl ophthalmic suspension 0.05%
Livostin, update on, 1014 (Nov)
levofloxacin
exhibits activity against various pathogens, 1108 (Nov)
liability issues
managed care organizations and, 136 (Feb)
lidocaine HCl 2% with epinephrine 1:100,000

Iontocaine, update on, 640 (Aug)
lisinopril
Prinivil, Zestril, update on, 89 (Feb)
loratidine/pseudoephedrine sulfate tablets
Claritin-D 24-hour Extended-Release tablets, update on, 1146 (Dec)
lovastatin
Mevacor, update on, 450 (Jun)
more effective but costlier than stepped-care Tx for lowering LDL cholesterol (abstr), 717 (Aug)

M

managed care
average length of stay and, 526 (Jun)
future of, 523 (Jun); 617 (Jul)
managing risks, improving outcomes in, 1017 (Nov)
market, HMOs top, 1028
setting, open formularies improve oncology outcomes in, 878 (Oct)
managed care organizations
changing from open to closed formularies in, 208 (Mar)
competition among, 654 (Aug)
increased number of, will improve costs, outcomes, 261 (Apr)
liability issues, and, 136 (Feb)
patients' rights, responsibilities in, 164 (Mar)
price-fixing lawsuit and, 358 (May)
Medicaid
DUR program, cost-effectiveness of, 95 (Feb)
Medi-Cal
newer antidepressants, adds to formulary, 354 (May)
medical research centers
government policies and, 422 (May)
Medicare
enrollment in, increasing dramatically, 884 (Oct)
mental illness
64 drugs in development for Tx of, 562 (Jul)
meropenem for injection
fever in patients with cancer who are granulocytopenic, for Tx of (abstr), 984 (Oct)
focus on, 759 (Sep)
Merrem IV, update on, 735 (Sep)
mesalamine, polymer-coated oral
colitis, for Tx of (abstr), 532 (Jun)
methotrexate/sulfasalazine/hydroxychloroquine sulfate
rheumatoid arthritis, for Tx of (abstr), 854 (Sep)
methylphenidate HCl
Ritalin, update on, 160 (Mar)
midodrine HCl
ProAmatine, update on, 1007 (Nov)
mirtazapine
focus on, 455 (Jun)
Remeron Tablets, update on, 736 (Sep)
mitoxantrone HCl
hormone-refractory prostate cancer, for Tx of, 654 (Aug)
morphine capsules
Kadian, update on, 872 (Oct)
mupirocin
Bactroban Nasal, update on, 1010 (Nov)
myocardial infarction
first, pravastatin reduces risk of, 65 (Jan)
thrombolysis vs angioplasty for Tx of, 411 (May)

N

naftifine HCl
idimazole, vs, for Tx of tinea pedis, 1119 (Nov)
naproxen sodium
Naprelan, update on, 346 (May)
National Council on Patient Information and Education, The
focus of, in 1996, 389 (May)
neurologic drugs
117 new, in development at end of 1995, 15 (Jan)
neutropenia, febrile
cefepime for Tx of, 1112 (Nov)
nevirapine
Viramune, update on, 160 (Mar); 736 (Sep)
nifedipine
Adalat, Procardia, update on, 351 (May)
nifedipine GI therapeutic systems (GITS)
switching from, to extended-release felodipine (abstr), 717 (Aug)
nilutamide
focus on, 105 (Feb)
Nilandron, update on, 1142 (Dec)
nisoldipine
Sular, update on, 87 (Feb)
nitazoxanide
AIDS-related cryptosporidial diarrhea, appears effective for the Tx of, 1111 (Nov)
non-Hodgkin's lymphoma
IDEC-C2B8 for Tx of, 705 (Aug)
nonsteroidal anti-inflammatory drugs
stepped-care protocol cost-effective for prescribing of (abstr), 849 (Sep)

O

obesity
dexfenfluramine for management of, 659 (Aug)
off-label drug uses
prescription benefits and, 90 (Feb)
ofloxacin
community-acquired pneumonia, for empiric Tx of (abstr), 718 (Aug)
converting to use of, as only quinolone on formulary, 906 (Oct)
Floxin, update on, 160 (Mar)
Ocuflox, update on, 640 (Aug)
urinary tract infection, cost-effective for Tx of, 1105 (Nov)
olanzapine
Zyprexa, update on, 1142 (Dec)
omeprazole
Prilosec, update on, 448 (Jun)
omeprazole/clarithromycin
Prilosec/Biaxin, update on, 642 (Aug)
ondansetron HCl
granisetron, vs, cost-effectiveness of, 49 (Jan)
Zofran, update on, 1014 (Nov)
osteoarthritis
nonopioid analgesics and NSAIDs for Tx of, 16 (Jan)
osteoporosis
alendronate for Tx of, 23 (Jan)
outcome measures
collecting and use of, 710 (Aug)
outcomes research
promoting practice, science of, 197 (Mar)
oxybutynin chloride
urinary incontinence, becomes agent of choice for Tx of, 564 (Jul)
oxycodone HCl
Oxycontin, update on, 642 (Aug); 877 (Oct)

P

paclitaxel/cisplatin
nonsmall-cell lung cancer, for Tx of, 751 (Sep)
pain management
delegating to pharmacists, 204 (Mar)
pamidronate disodium for injection
Aredia, update on, 12 (Jan); 1010 (Nov)
Parkinson's disease
ropinirole for Tx of, 440 (Jun)
selegiline slows progression of, 354 (May)
paroxetine HCl
Paxil, update on, 351 (May); 558 (Jul)
patient assistant programs
administration of, 1027 (Nov)
patient privacy
concerns regarding, 990 (Oct)
penciclovir cream
Denavir, update on, 1137 (Dec)
pentamidine isethionate
NebuPent, update on, 447 (Jun)
pentosan polysulfate sodium
Elmiron, update on, 1137 (Dec)
pharmaceutical companies
using informational support from, 614 (Jul)
pharmaceutical intervention
calculating cost-avoidance to document worth of, 207 (Mar)
pharmacists
counselling of patients by, 712 (Aug)
delegating pain management to, 204 (Mar)
roles and responsibilities of (abstr), 1120 (Nov)
pharmacoeconomic analyses
discounting in, 1217 (Dec)
pharmacoeconomics
advice regarding, 958 (Oct)
development of consensus guidance for evaluations of, 978 (Oct)
experience with, in Australia, 977 (Oct)
promoting practice, science of, 197 (Mar)
Pharmacy & Therapeutics Committees
consolidation of, in integrated health care system, 497 (Jun)
consolidation of multiple, 132 (Feb)
physician report cards
improving acceptance, usefulness of, 213 (Mar)
piperacillin sodium/tazobactam sodium
Zosyn, update on, 742 (Sep)
platelet recovery
post-chemotherapy, thrombopoietin accelerates, 706 (Aug)
pneumonia, community-acquired
ceftizoxime vs ceftriaxone for Tx of, 221 (Mar); 437 (Jun)
ofloxacin for Tx of (abstr), 718 (Aug)
twice-daily dosing of ceftizoxime for Tx of, 304 (Apr); 437 (Jun)
Polifeprosan 20 with carmustine implant
Gliadel wafer, update on, 1147 (Dec)
porfimer sodium
Photofrin, update on, 341 (May), 1145 (Dec)
practice guidelines
encouraging physician acceptance of, 525 (Jun)
pravastatin sodium
cost-effective for secondary prevention of coronary artery disease (abstr), 1242 (Dec)
first myocardial infarction, reduces risk of, 65 (Jan)
Pravachol, update on, 558 (Jul); 870 (Oct)
prevents cardiac events in men with hyperlipidemia but no history of MI (abstr), 322 (Apr)
slows disease progression in atherosclerosis and MI (abstr), 327 (Apr)
prednicarbate cream 0.1%
Dermatop, update on, 872 (Oct)
prescribing errors
avoiding, 1018 (Nov)
pharmacists catch potentially severe, 1106 (Nov)
prescription benefits
off-label drug uses and, 90 (Feb)
procainamide

Procanbid, update on, 448 (Jun)
prostate cancer
Nilandron, update on, 1142 (Dec)
protease inhibitors
potential for spontaneous bleeding in HIV-infected hemophiliacs treated with, 877 (Oct)
psychotic disorders
Zyprexa, update on, 1142 (Dec)
pulmonary embolism
shortened streptokinase regimen vs t-PA for Tx of, 1115 (Nov)

Q

quinupristin-dalfopristin
Synercid, update on, 13 (Jan)
vancomycin resistance, effective in patients with, 1020 (Nov)

R

ranitidine bismuth citrate
Tritec, update on, 1008 (Nov)
recombinant human insulin-like growth factor I
ALS, improves symptoms of, 15 (Jan)
remifentanil HCl
Ultiva, update on, 1008 (Nov)
respiratory syncytial virus immune globulin IV (human) RespiGam, update on, 251 (Apr)
ribavirin
monotherapy with, has limited effects on hepatitis C virus (abstr), 324 (Apr)
rifampin
cefixime, vs, for prophylaxis against group A streptococci (abstr), 322 (Apr)
riluzole
Rilutek, update on, 152 (Mar)
risk share programs
between MCOs and pharmaceutical industry, 309 (Apr)
implementing, 310 (Apr)
risperidone
Risperdal, update on, 872 (Oct)
ritonavir
Norvir, update on, 341 (May); 444 (Jun)
update on, 13 (Jan)
ritonavir/saquinavir
HIV viral load, shown to reduce, 1112 (Nov)
ropinirole
Parkinson's disease, for Tx of, 440 (Jun)
ropivacaine HCl
Naropin, update on, 1141 (Dec)
rotavirus vaccine, reassortant tetravalent
diarrhea, prevents, 1106 (Nov)

S

saquinavir mesylate
focus on, 265 (Apr)
Invirase, update on, 84 (Feb)
schizophrenia
sertindole for Tx of, 651 (Aug)
selegiline
Eldepryl, update on, 642 (Aug)
Parkinson's disease, slows progression of, 354 (May)
sertindole
schizophrenia, for Tx of, 651 (Aug)
serotonin reuptake inhibitors
selective tricyclics, preferred over, as first-line therapy for depression (abstr), 849 (Sep)
simvastatin
coronary heart disease, for Tx of patients with (abstr), 988 (Oct)
sinusitis, acute
Cefzil, update on, 1145 (Dec)
small cell lung cancer
Verluma, update on, 1142 (Dec)
sodium phenylbutyrate
Buphenyl, update on, 731 (Sep)
somatropin
Genotropin, update on, 154 (Mar)
Humatrope, update on, 1145 (Dec)
Nutropin AQ, update on, 642 (Aug)
Serostim, update on, 1013 (Nov)
Staphylococcus aureus
prevalence, antibiotic resistance on rise (abstr), 1245 (Dec)
stavudine
Zerit, update on, 554 (Jul)
Streptococcus pneumoniae
penicillin-resistant, clinical relevance of (commentary), 430 (Jun)
streptokinase
shortened regimen with, vs t-PA for Tx of pulmonary embolism, 1115 (Nov)
stroke, hemiplegic
fluoxetine enhances recovery of patients after (abstr), 987 (Oct)
stroke, ischemic
citicoline seems to limit immediate damage from, 561 (Jul)
t-PA improves outcomes from, 90 (Feb)
sulfonylurea/insulin
diabetes, for controlling (abstr), 416 (May)
sumatriptan succinate
Imitrex, update on, 1010 (Nov)
surgery
drugs used in, analyzing cost-effectiveness of, 817 (sep)

T

tamoxifen citrate
Nolvadex, update on, 13 (Jan)
technetium Tc 99m nofetumomab merpentan
Verluma, update on, 1142 (Dec)
technetium Tc 99m Sestamibi kit
Cardiolite, update on, 447 (Jun)
technetium Tc 99m tetrofosmin for injection
Myoview, update on, 551 (Jul)
terazosin
more potent in all BPH patients, prostate size less important issue, 1162 (Dec)
terfenadine
Seldane, update on, 877 (Oct)
terfinabine HCl
imidazole, vs, for Tx of tinea pedis, 1119 (Nov)
Lamisil Tablets, update on, 640 (Aug)
thalidomide
update on, 448 (Jun)
therapeutic interchange
HMOs using more, 351
using cost-effectiveness analysis to select drugs for, 603 (Jul)
3-TC
see *lamivudine*
thrombolysis
angioplasty, vs, for Tx of MI, 411 (May)
thrombopoietin, recombinant human
platelet recovery after chemotherapy, accelerates, 706 (Aug)
thromboprophylaxis program
pharmacist-run, evaluating costs of, 276 (Apr)
tinea pedis
imidazole vs allylamines for Tx of, 1119
tissue plasminogen activator
ischemic stroke, improves outcomes from, 90 (Feb)
pulmonary embolism, 1115 (Nov)
streptokinase, vs shortened regimen of, for Tx of, 1115 (Nov)
tobramycin
once-daily dosing of, 34 (Jan)
topotecan HCl
Hycamtin, update on, 735 (Sep)
tramadol
Ultram, update on, 450 (Jun)
trandolapril
Mavik, update on, 551 (Jul)
tretinoin
Vesanoid, update on, 87 (Feb)
tretinoin emollient cream
Renova 0.05%, update on, 154 (Mar)
triamcinolone acetonide
Nasacort AQ Nasal Spray, update on, 642 (Aug)
Nasacort Nasal Inhaler, update on, 640 (Aug)
triazolam tablets
Halcion, Xanax, update on, 872 (Oct)
tricyclic antidepressants
selective serotonin reuptake inhibitors preferred over, for Tx of depression (abstr), 849 (Sep)
tuberculosis
treatment approach curbs costs, mortality, 1155 (Dec)
typhoid Vi polysaccharide vaccine
Typhim Vi, update on, 558 (Jul)

U

ulcer, peptic
Helicobacter pylori eradication stressed for Tx of (abstr), 530 (Jun)
multidrug regimen recommended for curing *Helicobacter pylori* infection in patients with (abstr), 982 (Oct)
urinary incontinence
revised guidelines for Tx of, 564 (Jul)
urinary tract infection
ofloxacin cost-effective for Tx of, 1105 (Nov)
urofollitropin for subcutaneous injection
Fertinex, update on, 1014 (Nov)

V

valacyclovir HCl
Valtrex, update on, 158 (Mar)
vancomycin
quinupristin-dalfopristin effective in patients with resistance to, 1020 (Nov)
resistance to, despite usage restrictions, 1105 (Nov)
verapamil HCl, sustained-release
Covera-HS, update on, 346 (May)
Verelan, update on, 647 (Aug)
vinorelbine/cisplatin
nonsmall-cell lung cancer, for Tx of, 705 (Aug)

W

warfarin
adjusted-dose best for high-risk atrial fibrillation (abstr), 1245 (Dec)
West of Scotland Study
results from (abstr), 322 (Apr)

Z

zafirlukast
Accolate, update on, 1134 (Dec)
focus on, 1029 (Nov)

Continued

AUTHOR INDEX TO VOLUME 31

A

Amaya-Diaz, Analiza: See Okpara, Alphonsus U.
Ament, Paul W.; Pohland, Lisa J.; Matanin, Dean; McGuire, Walter M.: Controlling bacterial resistance by suppressing microbiological susceptibility data, 70 (Jan)
Amin, Khodayar: See Colodny, Lisa R.
Ashworth, Laurel; edited by Chow, Moses S.S.: Focus on alendronate: A nonhormonal option for the treatment of osteoporosis in postmenopausal women, 23 (Jan)

B

Bache, Thom: See Fetrow, Charles W.
Baldinger, Sandra L.; DeFusco, Patricia; edited by Chow Moses S.S.: Focus on Anastrozole: An aromatase inhibitor for the treatment of hormonally dependent advanced breast cancer, 363 (May)
Baldinger, Sandra L.; Shore, Eric T.; edited by Chow, Moses S.S.: Focus on zafirlukast: A leukotriene receptor antagonist for the prophylaxis and chronic treatment of asthma, 1029) (Nov)
Basskin, Lorne (editor)
Discounting in pharmacoeconomic analyses: When and how to do it, 1217 (Dec)
How to analyze the cost-effectiveness of drugs used in surgery, 817 (Sep)
How to collect and analyze costs associated with adverse drug events, 399 (May)
How to target adverse drug events using cost-benefit analysis, 507 (Jun)
How to use cost-effectiveness analysis to select drugs for therapeutic substitution, 603 (Jul)
Using cost-utility analysis to select among clinical pharmacy services, 684 (Aug)
Using value analysis to select formulary drugs from among similar agents, 1083 (Nov)
What to do when your service has been declared "cost-ineffective," 933 (Oct)
Bazunga, Munama; Chow, Moses S.S.: Reassessing antihypertensive agents in the post-JNC V era, 116 (Feb)
Becker, Amy J.; Mutnick Alan H.; Ross, Mary B.; Stilwell, Amy A.; Riggs, Charles E.; Hanson, Don B.: Combining a clinical trial with decision analysis to evaluate antiemetic agents, 670 (Aug)
Bowman, Gerald K; Moleski, Ron; Mangi, Richard J.: Measuring the impact of a formulary decision: Conversion to one quinolone agent, 906 (Oct)
Bowman, Lee: Using national and institutional economic data to target cost-effective use of abciximab, 186 (Mar)
Braman, Karen S.: See Sanborn, Michael D.
Briceland, Laurie L.; Tobin, Ellis H.; edited by Chow, Moses S.S.: Focus on meropenem: A broad-spectrum parenteral carbapenem antimicrobial agent, 759 (Sep)
Bullman, William Ray (interview): The National Council on Patient Information and Education: Focusing on communication, compliance, FDA MedGuide proposal in 1996, 389 (May)

C

Carter, Mike: See Dillon-Bader, Victoria L.
Chapela, Elyse Santome: See Dillon-Bader, Victoria L.
Chen, Bonnie P.; Chow, Moses S.S.; Kluger Jeffrey; edited by Chow, Moses S.S.: Focus on IV ibutilide: A new antiarrhythmic agent for the acute treatment of atrial fibrillation and flutter, 570 (Jul)
Chow, Moses S.S.
See Ashworth, Laurel
See Baldinger, Sandra L.
See Bazunga, Munama
See Briceland, Laurie L.
See Chen, Bonnie P.
See Dong, Betty J.
See Kehoe, William A.
See Martin, William R.
See Owens, Christy A.
See Udeh, Elizabeth
See White, C. Michael
Cohen, Myron S.: Concern regarding use of ceftizoxime over ceftriaxone for Tx of uncomplicated community-acquired pneumonia (letter), 437 (Jun)
Colodny, Lisa R.: Formulary maintenance programs: Preferential agents and cost savings, 1096 (Nov)
Colodny, Lisa R.; Amin, Khodayar: Using pharmacy services to promote compliance with renal dosing of antibiotics, 834 (Sep)
Cunha, Burke A.: See Klein, Natalie C.

D

DeFusco, Patricia: See Baldinger, Sandra L.
Dillon-Bader, Victoria L.; Glenski, Stephen; Vickers, Mary; Carter, Mike; Chapela, Elyse Santome: Results of a cetriaxone-to-ceftizoxime switch program for Tx of uncomplicated community-acquired pneumonia, 221 (Mar)
Dong, Betty J.; edited by Chow, Moses S.S.: Focus on saquinavir: An HIV proteinase inhibitor for use with nucleoside analogues, 265 (Apr)

E

Egbunike, Ifeanyi G.: See Okpara, Alphonsus U.
Enigbokan, Mofolorunso A.: See Okpara, Alphonsus U.

F

Fetrow, Charles W.; Bache, Thom; James, Gerri; Iqbal, Zafar: Development of a treatment protocol for hemodialysis-induced hypotension, 126 (Feb)

G

Gannon, Patrick: See Mucciardi, Nick
Glenski, Stephen: See Dillon-Bader, Victoria L.
Gonzalez, Edgar R.: Preventing cardiovascular atherosclerosis: Role of HMG-CoA reductase inhibitors, 582 (Jul)
Goodin, Susan; Gosland, Michael: Evaluation of 5-HT$_3$-receptor antagonists in emetogenic chemotherapy regimens, 1071 (Nov)
Gosland, Michael: See Goodin, Susan
Grant, Kathryn L.: Use of an algorithm to speed up, streamline the formulary review process, 404 (May)
Greist, John H.: See Katzelnick, David J.

H

Hanson, Don B.: See Becker, Amy J.
Henk, Henry J.: See Katzelnick, David J.
Herbert, William J.; Mahaney, Lynnae M.: Consolidating P & T Committees in an integrated health care system, 497 (Jun)

I

Iqbal, Zafar: See Fetrow, Charles W.

J

James, Gerri: See Fetrow, Charles W.
Jefferson, James W.: See Katzelnick, David J.
Johnson, Philip E.: Developing a reimbursement management plan for high-cost biologic agents, 293 (Apr)

K

Katzelnick, David J.; Kobak, Kenneth A.; Jefferson, James W.; Greist, John H.; Henk, Henry J.: Prescribing patterns of antidepressant medications for depression in a HMO, 374 (May)
Kazanjian, Powel: See MacDonald, Laurie
Kehoe, William A.; Schorr, Robert B.; edited by Chow, Moses S.S.: Focus on mirtazapine: A new antidepressant with noradrenergic and specific serotonergic activity, 455 (Jun)
Klein, Natalie C.; Cunha, Burke A.: Antibiotic approaches to therapy for Legionnaire's disease: A review, 808 (Sep)
Kluger, Jeffrey: See Chen, Bonnie P.
Kobak, Kenneth A.: See Katzelnick, David J.

L

Lewis, Jed S.: Using a DUE to improved the prescribing of oral ciprofloxacin in an outpatient population, 694 (Aug)

M

MacDonald, Laurie; Kazanjian, Powel:
Antiretroviral therapy in HIV infection: An update, 780 (Sep)
Opportunistic infections in patients with AIDS: Treatment and prophylaxis, 470 (Jun)
Mahaney, Lynnae M.: see Herbert, William J.
Mangi, Richard J.: See Bowman, Gerald K.
Martin, William R.; edited by Chow, Moses S.S.
Focus on docetaxel: A new antineoplastic agent approved by the FDA for the treatment of locally advanced or metastatic breast cancer, 891 (Oct)
Focus on nilutamide: A nonsteroidal antiandrogen for treatment of advanced prostate cancer, 105 (Feb)
Maswoswe, Jordan J.: See Okpara, Alphonsus U.
Matanin, Dean: See Ament, Paul W.
McCloskey, Barbara A.: Enhancements in an ADR program increase reports, improve patient care, 949 (Oct)
McGhan, William F. (interview): Association for Pharmacoeconomic and Outcomes Research: Promoting the practice and science of pharmacoeconomics and outcomes research, 197 (Mar)
McGuire, Walter M.: See Ament, Paul W.
Milch, Laura; White, C. Michael; Wolf, Scott: Focus on inhaled fluticasone propionate: A corticosteroid inhaler for use in the management of asthma, 1165 (Dec)
Moleski, Ron: See Bowman, Gerald K.

Mucciardi, Nick; Sesin, G. Paul; Gannon, Patrick: Successful clinical outcomes and cost-savings associated with a 12-hour IV ceftizoxime regimen, 304 (Apr)
Mutnick, Alan H.: See Becker, Amy J.

N

Nicolau, David: See Quintiliani, Richard
Nightingale, Charles H: See Quintiliani, Richard

O

Okpara, Alphonsus U.; Amaya-Diaz, Analiza; Egbunike, Ifeanyi G.; Maswoswe, Jordan J.; Enigbokan, Mofolorunso A.: Evaluating once-daily dosing of aminoglycosides: An observational study, 34 (Jan)
Owens, Christy A.; Chow, Moses S.S.; edited by Chow, Moses S.S.: Focus on dexfenfluramine: A serotonin reuptake inhibitor for the management of obesity, 659 (Aug)

P

Pohland, Lisa J.: See Ament, Paul W.

Q

Quintiliani, Richard; Nightingale, Charles H.; Nicolau, David: The clinical relevance of penicillin-resistant *Streptococcus pneumoniae*, 430 (May)

R

Rho, Jay P.: See Wong-Beringer, Annie
Riggs, Charles E.: See Becker, Amy J.
Ross, Mary B.: See Becker, Amy J.

S

Saltiel, Emmanuel; Shane, Rita: Evaluating costs of a pharmacist-run thromboprophylaxis program, 276 (Apr)
Sanborn, Michael D.; Braman, Karen S.; Weinhold, Frank E.: Using multidisciplinary quality focus teams to develop 5-HT_3 antagonist guidelines, 49 (Jan)
Schorr, Robert B.: See Kehoe, William A.
Sesin, Paul: See Mucciardi, Nick
Shane, Rita: See Saltiel, Emmanuel
Shane, Rita; Zakowski, Phillip (interview): Formulary management in the 1990s: Cedars-Sinai Medical Center's approach, 917 (Oct)
Shore, Eric T.: See Baldinger, Sandra L.
Spruill, William J.: See Wade, William E.
Stilwell, Amy A.: See Becker, Amy J.

T

Taniguchi, George: Fluoxetine DUE in a psychiatric population, 842 (Sep)
Taylor, A. Thomas: See Wade, William E.
Tobin, Ellis H.: See Briceland, Laurie L.

U

Udeh, Elizabeth; Chow, Moses S.S.: Acute hypertension: An appraisal of new and old pharmacologic agents, 1178 (Dec)
Vickers, Mary: See Dillon-Bader, Victoria L.

W

Wade, William E; Taylor, A. Thomas; Spruill, William J.: Using published, institutional data to evaluate the cost effectiveness of DVT prophylaxis, 1203 (Dec)
Wechsler, Jill
AHCPR promotes research to avoid ax, 138 (Feb)
Congress expands insurance availability, codifies MedGuide proposal, 856 (Sep)
Court ruling on discriminatory pricing may alter pharmaceutical discounts, 720 (Aug)
Electronic transmission, sharing of health information raising patient privacy concerns, 990 (Oct)
FDA proposes changes in drug information regulations to prevent congressional action, 624 (Jul)
FDA reform legislation gains attention but enactment uncertain, 330 (Apr)
FDA "reinvention" efforts block reform legislation, 1122 (Nov)
Focus on formularies, FDA in the year ahead, 74 (Jan)
Generic, proprietary drug manufacturers square off in patent extension debate, 534 (Jun)
Government policies aim to rescue medical research centers, 422 (May)
"No more drug lag," insists FDA, 236 (Mar)
Regulators, providers seek to reduce medication errors and adverse drug events, 1256 (Dec)
Weinhold, Frank E.: See Sanborn, Michael D.
White, C. Michael; Chow, Moses S.S.: Beyond ACE inhibition: The role of angiotensin II type 1 receptor blockers in cardiovascular disease, 1058 (Nov)
White, C. Michael: See Milch, Laura
Wolf, Scott: See Milch, Laura
Wong-Beringer, Annie; Beringer, Paul M.; Rho, Jay P.: Focus on amphotericin B lipid complex: For serious systemic mycoses in patients who are refractory to or intolerant of conventional amphotericin B, 169 (Mar)

Z

Zakwoski, Phillip: See Shane, Rita

CLASSIFIED ADS

For all ads under $250, payment must be received by the classified closing date. **VISA, MASTERCARD & AMERICAN EXPRESS ACCEPTED.** Credit card orders are accepted by phone. Send ad copy with payment to: Paula Alward, **FORMULARY**, 7500 Old Oak Blvd., Cleveland, OH 44130 or call 800-225-4569 ext. 611; 216-891-2611. Fax 216-826-2865. Call for 1997 rate information and closing dates.

The Benefits Of CLASSIFIED ADVERTISING

IMPACT
Command immediate attention and get fast action with the dynamics of classified advertising!

EXPOSURE
Reach highly targeted, market-specific business professionals, industry experts and prospects.

VALUE
Select from a variety of classified display options to meet specific needs on a timely basis cost-effectively.

RESULTS
Generate sales leads, maintain market presence, conduct market testing, promote existing lines, introduce new products and services, or recruit the best — bottom-line — classifieds offer you an excellent return on investment!

ADVANSTAR
MARKETING SERVICES
A Division of Advanstar Communications Inc.
7500 Old Oak Blvd.
Cleveland, OH 44130

SEND AD COPY WITH PAYMENT TO:

Paula Alward
FORMULARY
7500 Old Oak Blvd
Cleveland, OH 44130

For more information call
800-225-4569 ext. 611
216-891-2611
or fax ad copy to
216-826-2865